Lipocine Inc.

8-K · form8-k.htm

0001535955

 2026-06-12
 2026-06-12

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

  

 FORM
 8-K

  

 CURRENT
REPORT

  

 Pursuant
to Section 13 or 15(d) of

 The
Securities Exchange Act of 1934

  

 Date
of Report (Date of Earliest Event Reported):

 June
12, 2026

  

  

 LIPOCINE
INC.

 (Exact
name of registrant as specified in its charter)

  

 Commission
File No. 001-36357

  

 Delaware
  
 99-0370688

 (State
 or other jurisdiction

 of
 incorporation)

  
 (IRS
 Employer

 Identification
 Number)

  

 675
Arapeen Drive , Suite 202

 Salt
Lake City , Utah 84108

 (Address
of principal executive offices) (Zip Code)

  

 Registrant’s
telephone number, including area code: (801) 994-7383

  

 Former
name or former address, if changed since last report: Not Applicable

  

  

  

 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

  

 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities
registered pursuant to Section 12(b) of the Act:

  

 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 Common
 Stock, par value $0.0001 per share
  
 LPCN
  
 The
 NASDAQ Stock Market LLC

  

 Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

  

 Emerging
growth company ☐

  

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item
 8.01
 Other
 Events

  

 On
June 12, 2026, the Company hosted a virtual key opinion leader (“KOL”) event highlighting
 the unmet needs in postpartum depression and the clinical profile
of LPCN 1154. The
presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein. A link to the presentation is available
on the corporate website
at www.lipocine.com .

  

 Item
 9.01
 Financial
 Statements and Exhibits.

  

 (d)
 Exhibits

  

 The
following exhibits are filed with this report:

  

 Exhibit
 No.
  
 Description

  
  
  

 99.1
  
 Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 Presentation

  
  
  

 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

  

  

  

  

 SIGNATURES

  

 Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  

  
  
  
 LIPOCINE
 INC.

  
  
  
  
  

 Date:
 June
12, 2026
  
 By:
 /s/
 Mahesh V. Patel

  
  
  
  
 Mahesh
 V. Patel

  
  
  
  
 President
 and Chief Executive Officer